The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used for the treatment of hematologic cancers and disorders. However, graft-versus-host disease (GVHD) in which the donor immune cells attack the genetically-disparate recipient is a significant cause of morbidity. Acute GVHD is an in...

Full description

Bibliographic Details
Main Authors: Lam T. Khuat, Maneesh Dave, William J. Murphy
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Gut Microbes
Online Access:http://dx.doi.org/10.1080/19490976.2021.1966262
id doaj-7c309182d1044d8fb600e5516c7f12aa
record_format Article
spelling doaj-7c309182d1044d8fb600e5516c7f12aa2021-09-06T14:06:26ZengTaylor & Francis GroupGut Microbes1949-09761949-09842021-01-0113110.1080/19490976.2021.19662621966262The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantationLam T. Khuat0Maneesh Dave1William J. Murphy2School of Medicine, University of CaliforniaSchool of Medicine, University of CaliforniaSchool of Medicine, University of CaliforniaAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is used for the treatment of hematologic cancers and disorders. However, graft-versus-host disease (GVHD) in which the donor immune cells attack the genetically-disparate recipient is a significant cause of morbidity. Acute GVHD is an inflammatory condition and the gastrointestinal system is a major organ affected but is also tied to beneficial graft-versus-tumor (GVT) effects. There is increasing interest on the role of the microbiome on immune function as well as on cancer progression and immunotherapy outcomes. However, there are still significant unanswered questions on the role the microbiome plays in GVHD progression or how to exploit the microbiome in GVHD prevention or treatment. In this review, concepts of HSCT with the focus on GVHD pathogenesis as well as issues in preclinical models used to study GVHD will be discussed with an emphasis on the impact of the microbiome. Factors affecting the microbiome and GVHD outcome such as obesity are also examined. The bridging of preclinical models and clinical outcomes in relation to the role of the microbiome will also be discussed along with possibilities for therapeutic exploitation.http://dx.doi.org/10.1080/19490976.2021.1966262
collection DOAJ
language English
format Article
sources DOAJ
author Lam T. Khuat
Maneesh Dave
William J. Murphy
spellingShingle Lam T. Khuat
Maneesh Dave
William J. Murphy
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
Gut Microbes
author_facet Lam T. Khuat
Maneesh Dave
William J. Murphy
author_sort Lam T. Khuat
title The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
title_short The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
title_full The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
title_fullStr The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
title_full_unstemmed The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
title_sort emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation
publisher Taylor & Francis Group
series Gut Microbes
issn 1949-0976
1949-0984
publishDate 2021-01-01
description Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used for the treatment of hematologic cancers and disorders. However, graft-versus-host disease (GVHD) in which the donor immune cells attack the genetically-disparate recipient is a significant cause of morbidity. Acute GVHD is an inflammatory condition and the gastrointestinal system is a major organ affected but is also tied to beneficial graft-versus-tumor (GVT) effects. There is increasing interest on the role of the microbiome on immune function as well as on cancer progression and immunotherapy outcomes. However, there are still significant unanswered questions on the role the microbiome plays in GVHD progression or how to exploit the microbiome in GVHD prevention or treatment. In this review, concepts of HSCT with the focus on GVHD pathogenesis as well as issues in preclinical models used to study GVHD will be discussed with an emphasis on the impact of the microbiome. Factors affecting the microbiome and GVHD outcome such as obesity are also examined. The bridging of preclinical models and clinical outcomes in relation to the role of the microbiome will also be discussed along with possibilities for therapeutic exploitation.
url http://dx.doi.org/10.1080/19490976.2021.1966262
work_keys_str_mv AT lamtkhuat theemergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation
AT maneeshdave theemergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation
AT williamjmurphy theemergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation
AT lamtkhuat emergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation
AT maneeshdave emergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation
AT williamjmurphy emergingrolesofthegutmicrobiomeinallogeneichematopoieticstemcelltransplantation
_version_ 1717779289756139520